Gossamer Bio, Inc. Quarterly Report Released - Here’s What You Should Know

Gossamer Bio, Inc. – Q3 2025 Investor Summary

Financial Position

• Cash, cash equivalents, and marketable securities as of September 30, 2025 were $180.2 million ($8.9 million cash/equivalents, $171.3 million marketable securities), down from $294.5 million at December 31, 2024.
• Total assets stood at $208.8 million, with total liabilities at $291.2 million, resulting in a stockholders’ deficit of $82.3 million (compared to $29.5 million equity at year-end 2024).

Results of Operations

• Revenue for Q3 2025 was $13.3 million (from Chiesi Collaboration), up from $9.5 million for Q3 2024.
• For the nine months ended September 30, 2025, total revenue was $34.7 million, significantly lower than $105.3 million in 2024 due to the absence of license sale revenue ($88.8 million recognized in 2024).
• Research and development (R&D) expenses increased to $45.5 million in Q3 2025 (from $34.9 million Q3 2024), and $125.2 million for the first nine months of 2025 ($102.4 million in 2024), mainly attributed to the Seralutinib program.
• General and administrative expenses were $9.4 million in Q3 and $26.7 million for the nine months, consistent year-over-year.
• Net loss for Q3 2025 was $48.2 million ($0.21/share), compared to $30.8 million ($0.14/share) in Q3 2024. For the nine months, net loss was $123.1 million ($0.54/share) versus $23.5 million in 2024.

Balance Sheet and Liquidity

• Convertible senior notes due 2027 have a principal balance of $200.0 million (net carrying amount $198.3 million).
• Operating activities used $123.0 million in cash for the nine months ended September 30, 2025 (prior year same period: $32.0 million provided).
• Investing activities provided $83.2 million, mainly from net maturities of marketable securities.
• The company expects current cash, equivalents, and marketable securities will fund operations for at least 12 months from the filing date.
• As of October 31, 2025, 231,456,247 shares of common stock were outstanding.

Collaborations & Agreements

• The Chiesi Collaboration remains the sole revenue driver; all nine months’ revenue was from this agreement (100% concentration).
• $51.1 million contract liability remains related to Chiesi, primarily allocated to ongoing research and development performance obligations.
• No new revenue from license sales was recognized in 2025; future milestone/royalty payments from collaborations not considered probable as of Q3 2025.

Stock and Equity

• 48.1 million stock options outstanding (weighted average exercise price $1.71), with 20.6 million exercisable at quarter-end; 2.7 million PSUs granted in 2025.
• Warrants outstanding: 32.0 million at quarter-end.
• Stock-based compensation totaled $7.7 million YTD 2025 (down from $15.7 million in 2024).

Risks and Considerations

• Substantial, recurring net losses and accumulated deficit ($1.39 billion as of September 30, 2025).
• Heavily reliant on a single collaboration partner (Chiesi) and a single clinical program (Seralutinib), with successful further development and commercialization required for revenue sustainability.
• Future capital requirements significant; company may need to raise additional funds or seek new partnerships.
• No material legal proceedings or changes in identified risk factors from previous filings.
• The fair value of the company’s 2027 Notes was $142.5 million as of September 30, 2025 (principal $200 million).

Conclusion Gossamer Bio’s cash position remains sufficient for near-term operations, but the company is deeply unprofitable with a growing deficit and heavy dependence on the Chiesi partnership and progress of seralutinib. The absence of new license sales, increasing R&D spend, and reliance on external capital raise the risk profile for shareholders until clinical and commercial milestones are achieved.

Visit Publicview AI to search and analyze millions of SEC filings using AI.